Dr. Lisa M. Lepeak
Claim this profileDean Hematology and Oncology Clinic
Area of expertise
Chronic Lymphocytic Leukemia
Lisa M. Lepeak has run 1 trial for Chronic Lymphocytic Leukemia. Some of their research focus areas include:
Lymphoma
Lisa M. Lepeak has run 1 trial for Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Dean Hematology And Oncology Clinic
SSM Health Dean Medical Group - Baraboo
Clinical Trials Lisa M. Lepeak is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting
2 awards
Phase 3
32 criteria
Text-Based Smoking Cessation Program
for Rural Cancer Survivors
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Recruiting
2 awards
Phase 3
More about Lisa M. Lepeak
Clinical Trial Related
7 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Lisa M. Lepeak has experience with
- Ibrutinib
- Obinutuzumab
- Venetoclax
- Carboplatin
- Pembrolizumab
- Pemetrexed
Breakdown of trials Lisa M. Lepeak has run
Chronic Lymphocytic Leukemia
Lung Cancer
Non-Small Cell Lung Cancer
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lisa M. Lepeak specialize in?
Lisa M. Lepeak focuses on Chronic Lymphocytic Leukemia and Lymphoma. In particular, much of their work with Chronic Lymphocytic Leukemia has involved Stage I patients, or patients who are Stage II.
Is Lisa M. Lepeak currently recruiting for clinical trials?
Yes, Lisa M. Lepeak is currently recruiting for 2 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Lisa M. Lepeak has studied deeply?
Yes, Lisa M. Lepeak has studied treatments such as Ibrutinib, Obinutuzumab, Venetoclax.
What is the best way to schedule an appointment with Lisa M. Lepeak?
Apply for one of the trials that Lisa M. Lepeak is conducting.
What is the office address of Lisa M. Lepeak?
The office of Lisa M. Lepeak is located at: Dean Hematology and Oncology Clinic, Madison, Wisconsin 53717 United States. This is the address for their practice at the Dean Hematology and Oncology Clinic.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.